NCT06308575View on ClinicalTrials.gov

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 5, 2024

Study Completion Date

November 5, 2024

Conditions

Metastatic Olfactory NeuroblastomaRecurrent Olfactory Neuroblastoma

Interventions

DRUG

Rivoceranib

Given by PO

Sponsors

Collaborators (1)

Elevar Therapeutics

All Listed Sponsors

collaborator

Elevar Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06308575 - A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | Biotech Hunter | Biotech Hunter